መነሻ › አኩት ማይሎይድ ሊውኬሚያ › Vermont
በVermont ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 7 ጥናቶች በVermont ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በVermont ውስጥ ያሉ ከተሞች
Official study text (English)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Vermont Medical Center, Burlington
- University of Vermont and State Agricultural College, Burlington
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Vermont and State Agricultural College, Burlington
ተሳታዮችን በመፈለግ ላይደረጃ 3
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Vermont Medical Center, Burlington
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Vermont, Burlington
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።